P8A:SGX
Cordlife Group Ltd
0,12 SGD
0,00%
(0,00) 1D
12 tet, 9:49:20 p.d., GMT+8 · SGD
search
Të gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për P8A...
Kapitalizimi i tregut
32,37 mln
Vëllimi mesatar
1,32 mijë
Vëllimi
0,00
Maksimumi 52-javor
0,26 SGD
Minimumi 52-javor
0,10 SGD
Fitimet për aksion
-0,04 SGD
Aksionet në qarkullim
267,53 mln
Numri i punonjësve
111
Kapitalizimi i tregut
32,37 mln
Vëllimi mesatar
1,32 mijë
Vëllimi
0,00
Maksimumi 52-javor
0,26 SGD
Minimumi 52-javor
0,10 SGD
Fitimet për aksion
-0,04 SGD
Aksionet në qarkullim
267,53 mln
Numri i punonjësve
111
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
MarketBeat
·
28 minuta më parë
SK hynix Inc. (NASDAQ:SKHY) Stock Has Consensus Target Price of $253.22
NDTV Profit
·
23 minuta më parë
84% Stocks In Correction, Yet S&P 500 At Record Highs: What's Behind The 'Bull-Bear' Market?
MarketBeat
·
28 minuta më parë
Caris Life Sciences, Inc. (NASDAQ:CAI) Stock Has Average Target Price of $27.82 According to Brokerages
Yahoo Finance
·
20 orë më parë
Wall Street’s record breakouts unravel as investors dump recent winners: Chart of the Day
Profili
Cordlife Group Limited, is a consumer health company incorporated in May 2001 and a provider of cord blood and cord lining banking services in Asia. Cordlife has been listed on the mainboard of SGX since March 2012.
Cordlife Group owns the largest network of cord blood banks in Asia with full stem cell processing and storage facilities in six markets including Singapore, Hong Kong, India, Indonesia, and the Philippines. Beyond cord blood and cord lining banking, Cordlife offers diagnostics services, particularly for the mother and child segment, including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening and family genetic screening services.
Cordlife's stem cell processing and storage facilities in Singapore, Hong Kong, India, Indonesia, the Philippines and Malaysia were accredited by AABB until 2024 when its accreditation was withdrawn.
In November 2023, the Ministry of Health of Singapore revealed that Cordlife Group had exposed cryopreserved cord blood units at suboptimal temperatures, damaging the cord blood units belonging to at least 2,150 clients and rendering them unsuitable for stem cell transplant purposes. Wikipedia
Rreth Cordlife Group Ltd
Drejtori ekzekutivYiu Pang Fai
Punonjësit111
Themeluar më2 maj 2001
Selia-
SektoriHealth care provider
Uebsajticordlife.com